# The Prevalence of Human Papillomavirus Genotypes in Women with Precancerous Lesions and Cervical Cancer in Arequipa, Peru

## TL;DR

This study analyzed HPV genotypes in women with cervical issues in Arequipa, Peru, finding that HPV-16 was most common in older women with severe lesions.

## Contribution

The study provides insights into HPV genotype distribution in cervical cancer and precancerous lesions in a specific Peruvian population.

## Key findings

- HPV-16 was most prevalent in CIN 3 cases among women over 35.
- Other high-risk HPV genotypes were more frequent than HPV-16 in cervical cancer cases.
- HPV-16 was the most common individual high-risk genotype in CIN-3 in women ≥35 years.

## Abstract

The objective of this study was to determine the relationship between the prevalence of high-risk human papillomavirus (HRHPV) and age in women with cervical neoplasia or cervical cancer. This retrospective study involved 470 women referred for abnormal cervical cytology between January 2021 and December 2023. The Cobas 4800 test was used to identify HRHPV genotypes; it specifically identified genotypes 16 and 18 and grouped the other high-risk genotypes into another category. The Cobas 4800 test was performed together with colposcopy and biopsies of cervical lesions. From the analysis, we selected 470 women who underwent cervical biopsies and HPV testing. Of them, 208 (44.3%) were HPV-negative. Among the 262 women positive for HPV, 13.0% were positive for genotype 16 only, 1.3% for genotype 18 only, and 35.1% for other HPV genotypes. HPV-16 was found in 58.3% of cases of cervical intraepithelial neoplasia grade 3 (CIN 3) in women under 35 years of age and in 20.9% of cases in women over 35 years of age. Furthermore, 51.9% of patients with cervical cancer tested positive for other high-risk HPV types, whereas 30.8% had HPV-16. Although other HPV genotypes were more frequent than HPV-16 and HPV-18 in individuals with cervical cancer, HPV-16 was the most common individual high-risk genotype in women ≥ 35 years of age with CIN-3.